Commentary: Another view of Biden's prescription drug cost initiative - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Washington Wire
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Washington Wire RSS Get our newsletter
Order Prints
March 25, 2024 Washington Wire
Share
Share
Post
Email

Commentary: Another view of Biden’s prescription drug cost initiative

By Brandon Newman

In his most recent State of the Union speech, President Joe Biden presented a detailed plan to combat the rising costs of prescription drugs, a major issue that affects millions of people in the U.S. Among the measures that Biden proposes is the limitation of out-of-pocket costs for prescription drugs while simultaneously allowing the federal government the right to negotiate drug pricing. This represents a considerable shift from the regulations that have been in place previously surrounding healthcare. Given my position as the CEO of Xevant, I offer my perspective on these developments.

prescription drug
Brandon Newman

While I sincerely support initiatives to make medications more affordable and accessible to the public, we must remain vigilant about the unintended implications of capping patient spending and enforcing government price setting. It is not surprising that the goal of these initiatives is to reduce the financial burdens that patients face. We applaud all efforts to help reduce the cost of medications, especially for patients who are facing an ever-increasing cost of health care. However, we must keep an eye on the unintended repercussions, such as reduced incentives for pharmaceutical companies to invest in innovative therapies. The balance of affordability with the sustainability of drug development must be taken into consideration to ensure long-term health outcomes.

These policies may prompt pharmaceutical companies to reassess their pricing strategies, potentially hindering investment in innovative treatments due to diminished expected returns. As industry stakeholders, we must advocate for policies that foster innovation while ensuring healthcare remains accessible to all. Our role includes facilitating dialogue between payers and manufacturers to find a middle ground that sustains innovation. Although the effort to cut medicine prices is admirable, we must not jeopardize the pharmaceutical industry's ability to innovate. Strategies including value-based pricing and fostering competition may help ensure that cost savings do not come at the expense of innovation or patient choice. The issue is about striking a balance that serves all stakeholders in the healthcare system.

Furthermore, the involvement of pharmacy benefit managers and other intermediaries is becoming increasingly crucial in the process of implementing changes to the regulatory framework. Through the usage of analytics and insights driven by data, we can assist our clients in shifting to new pricing structures while simultaneously preserving the provision of value to their members.

Finally, concerns regarding low out-of-pocket caps that may discourage manufacturers from dropping pricing or offering cheaper alternatives are reasonable. One thing I’d like to put emphasis on, though, is the strategic use of data analytics and collaboration with industry partners. This can lead to the development of solutions that drive price reductions while preserving a competitive market that promotes innovation. Our goal should be to guarantee that these rules result in a more efficient and effective healthcare system without inhibiting innovation.

Taking everything into consideration, Biden's proposals represent a significant step toward addressing the current issue of affordability of prescription drugs. However, it's essential for policymakers and industry stakeholders to work together to mitigate potential unintended consequences and ensure that these initiatives lead to positive outcomes for patients and the health care system as a whole.

 

Brandon Newman is CEO of Xevant. Contact him at brandon.newman@innfeedback.com.

 

© Entire contents copyright 2024 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.

Brandon Newman

Older

Long-term care insurance: Public v. Private – What’s working?

Newer

Regulators adopt first climate strategy in bid to boost insurance markets

Advisor News

  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
More Advisor News

Annuity News

  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity News

Health/Employee Benefits News

  • Picking Medicare insurance plan is daunting task – Healthful Hints
  • November Issue of Best’s Review Ranks US Life Reinsurers and More
  • New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
  • New Va. subsidies help lure people back to health insurance
  • 3 ways Crowley can make Healthcare more affordable in Wisconsin 3 ways to make healthcare more affordable in Wisconsin | Coleman Drake (Copy)
More Health/Employee Benefits News

Life Insurance News

  • November Issue of Best’s Review Ranks US Life Reinsurers and More
  • Nebraska widow’s big win against life insurer in legal limbo
  • New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • U-Haul Holding Company to Participate in Deutsche Bank Conference
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.